Intestinal mononuclear phagocytes as prognostic biomarker for crohn's disease
US-2024425923-A1 · Dec 26, 2024 · US
US9994898B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9994898-B2 |
| Application number | US-201214122871-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 7, 2012 |
| Priority date | Jun 7, 2011 |
| Publication date | Jun 12, 2018 |
| Grant date | Jun 12, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Materials and methods for identifying carriers of genetic determinants of spinal muscular atrophy are disclosed. In particular, polymorphisms in linkage disequilibrium are associated as markers of spinal muscular atrophy alleles detectable by various techniques, including multiplex ligation-dependent probe analysis, sequence analysis, and RFLP detection. The materials and methods of the disclosure are particularly useful in identifying silent (2+0) carriers of spinal muscular atrophy in which two copies of the SMN1 gene are located on a single human chromosome 5 and no copies of the gene are located on the chromosome 5 homolog.
Opening claim text (preview).
What is claimed is: 1. A method of determining the copy number of a SMN1 gene and detecting microsatellite alleles in a subject, the method comprising: (a) obtaining a DNA sample from the subject; (b) analyzing the DNA sample using multiplex ligation-dependent probe amplification (MLPA) to determine the SMN1 copy number in the subject; and (c) analyzing the DNA sample to detect the alleles present at least at three of four consecutive loci set forth as D5S681-D5S435-MS1-D5S610 in the subject's DNA. 2. The method of claim 1 , wherein analyzing to detect the alleles present includes detecting alleles of D5S681, D5S435, and MS1, and optionally the alleles of D5610, and wherein the method further includes determining a haplotype for the subject at those alleles, and wherein the subject is identified as at risk of being a silent carrier (2+0) of Spinal Muscular Atrophy (SMA) when SMN1 copy number is two and wherein the subject carries a haplotype for D5S681-D5S435-MS1-D5S610 that is 2-5-6-10, 2-5-4-5 or 2-5-4-9, or wherein the subject carries a haplotype for D5S681-D5S435-MS1 that is 2-5-6. 3. The method of claim 2 , wherein the haplotype for D5S681-D5S435-MS1-D5S610 is 2-5-6-10. 4. The method of claim 2 , wherein the haplotype for D5S681-D5S435-MS1 is 2-5-6. 5. The method of claim 1 , wherein analyzing to detect the alleles present includes detecting alleles of D5S681, D5S435, MS1, and D5610, and wherein the method further includes determining a haplotype for the subject at those alleles, and wherein the subject is identified as at risk of being a deletion carrier of Spinal Muscular Atrophy (SMA) when SMN1 copy number is one and wherein the subject carries a haplotype for D5S681-D5S435-MS1-D5S610 that is 2-1-4-5 or 2-5-4-5. 6. The method of claim 5 , wherein the haplotype for D5S681-D5S435-MS1-D5S610 is 2-5-4-5. 7. The method of claim 5 , wherein the haplotype for D5S681-D5S435-MS1-D5S610 is 2-1-4-5. 8. A method of identifying a subject with an increased risk of SNM1 duplication and an increased risk of being a carrier of Spinal Muscular Atrophy (SMA) comprising: (a) obtaining a DNA sample from the subject; (b) analyzing the DNA sample using multiplex ligation-dependent probe amplification (MLPA) to determine the SMN1 copy number in the subject; (c) analyzing the DNA to detect the alleles present at each of D5S681, D5S435, MS1 and D5S610; (d) detecting in the DNA sample the presence of a haplotype selected from the group consisting of (i) a haplotype comprising D5S681 having allele 2, D5S435 having allele 5, MS1 having allele 4, and D5S610 having allele 5; (ii) a haplotype comprising D5S681 having allele 2, D5S435 having allele 5, MS1 having allele 9, and D5S610 having allele 4; (iii) a haplotype comprising D5S681 having allele 2, D5S435 having allele 5, and MS1 having allele 6; and (iv) a haplotype comprising D5S681 having allele 2, D5S435 having allele 5, MS1 having allele 6, and D5S610 having allele 10; wherein the presence of two copies of SMN1 and the presence of the haplotype identifies the subject as having an increased risk of SMN1 duplication and an increased risk of being a carrier of SMA.
Polymorphic or mutational markers · CPC title
for diseases caused by alterations of genetic material · CPC title
for detection of mutation or polymorphism · CPC title
Haplotypes · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.